Layout nerve intervention full product line, Aiko Medical received more than 100 million B round financing.

Guide: Aiko Medical is pleased to receive financing, and the neuro-intervention product line is expected to improve again!----recently, arterial network learned that Aiko Medical Devices (Beijing) Co., Ltd(hereinafter referred to as "Aiko Medical") completed more than RMB 100 million b round of financing, the lead investor for Sequoia Capital China Fund, Huagai Capital and Investment, Hao Yue Capital as the exclusive financial adviser for this round of financingFounded in 2016 and headquartered in Beijing, China,Isco Medical is a full-line company in the field of neurointervention, based in California, USAChina has one of the highest rates of stroke (commonly known as "stroke") in the world, and has become the leading cause of death among Chinese patients for 20 consecutive years, with an overall death rate of more than 60%According to the China Stroke Prevention Report (2018),, there will be 31.77 million stroke patients nationwide by 2030the current number of stroke cases, mortality per 100,000 people exceedcardiovascular disease, but limited by treatment costs, the number of surgeons and the limited degree of department sinking and other factors, the current number of neuro-intervention surgery cases is only equivalent to the level of heart intervention in 2004, with the strengthening of medical policy support, surgical learning curve shorter and clinical trial data and other positive factors, neurointervention will usher in a golden decadethe "Healthy China 2030" Planning Outline has promoted the prevention and control of stroke as a national strategyin addition to the promotion of policies and strategies, the field of nerve intervention also presents a high-speed development trend, because of the high precision requirements in the art and so on, the market share of domestic brands is still very low, Medtronic, Stryker, Johnson and Johnson, Telmau and other giants monopoly situation, resulting in more than 90% of the market share firmly occupiedat this fast-growing track, Aiko Medical has completed innovative design selling a number of products and obtained the "Green Channel" of the National Drug Administration with its research and development team with a global vision and a deep understanding of pain points for clinical applications, the founder of Aiko Medical, says that in terms of the Chinese market, the new era of domestic devices should not be just simple imitations of imported productsdomestic or imported, Chinese doctors and patients should use the best products in the worldAiko Medical only wants to do everything in its power to give full play to china's respective strengths and hand over the world's most advanced neuro-interventional devices to Chinese doctorsthanked investors for their love and recognition, and thanked the old shareholders for their continued supportYang Yunxia, managing director of theSequoia Capital China Fund, said: "Cerebral vascular disease is a significant area of health threat, and the use of neurointerventionises has the potential to treat a significant number of cerebrovascular diseases more efficiently and safelyAiko medical team research and development experience, product technology characteristics clear, we look forward to working with the Aiko team and other investor partners to promote the company's rapid development, to bring higher quality products and services for patientsMeng Nan, executive general manager of Huagai Capital Medical Fund," said: "Aike Medical in the field of neuro-intervention product research and development strength, sales resource network, etcare first-class in the industry."'s research and development team in the United States has complete product development experience, the first clinical phase of the intracranial aneurysm blood flow guidance device has been recognized by innovative devices and clinicians, while the management team has a mature channel expansion capability, the commercial path after the product market can be expected, the future will become the field of neuro-intervention really affordable to withstand the test of the head enterpriseHuagai will continue to create business synergies for enterprises, to help the development of enterprisesYang Zhenjun, partner of", said: "Hao Yue Capital is honored to assist Aiko Medical to complete this round of financing, a good company not only needs excellent research and development strength, leading strategic vision is also the achievement of a unique characteristics of a company, these characteristics are also highly recognized by top investment institutions."after the successful completion of this round of financing, as the company accelerates the speed of pipeline research and development, product registration and listing is within reachWe believe that Aiko can use its technical advantages, in the capital of the increase, bigger and stronger product line, to become a leader in the field of nerve intervention"related labels: Beijing, nervous system, product line, Aiko Medical, financing success 00.